Patent Valuation, Monetization and Investments

Blog

Markman Advisors Patent Blog

by Zachary Silbersher

Posts tagged xanomeline
Will Bristol Myers’ patent gamble for Karuna’s KarXT pay off?

Bristol Myers Squibb recently announced a deal to buy Karuna Therapeutics for $14 billion.  Bristol Myers has touted the deal as accelerating the company’s expansion into neuroscience.  Karuna’s lead asset, KarXT, is an antipsychotic that is a combination of two prior drugs, xanomeline and trospium.  Analysts have reported that KarXT could surpass $6 billion in annual sales.  However, that may depend on whether Karuna has protected KarXT with sufficient intellectual property.  Does KarXT have strong enough patent protection to ward off generics for long enough to make Bristol Myers’ gamble pay off?

Read More